VCYT

Veracyte Inc

Sep 16 • 02:10PM ET

32.14

+0.27 0.85 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: EXAS ILMN GH BIO NTRA MYGN CDNA QGEN FLGT CRL

| Held by: IJR ARKK VTI IWM VB XBI FBT ARKG VBK VXF

Index	RUT	P/E	96.60	EPS (ttm)	0.33	Insider Own	2.25%	Shs Outstand	78.60M	Perf Week	0.47%
Market Cap	2.53B	Forward P/E	22.09	EPS next Y	1.45	Insider Trans	-1.10%	Shs Float	76.90M	Perf Month	6.35%
Enterprise Value	2.26B	PEG	1.33	EPS next Q	0.32	Inst Own	106.65%	Short Float	10.46%	Perf Quarter	20.65%
Income	26.34M	P/S	5.28	EPS this Y	360.93%	Inst Trans	7.07%	Short Ratio	5.58	Perf Half Y	2.91%
Sales	479.13M	P/B	2.07	EPS next Y	1.82%	ROA	2.04%	Short Interest	8.04M	Perf YTD	-18.84%
Book/sh	15.54	P/C	7.88	EPS next 5Y	72.79%	ROE	2.24%	52W High	47.32 -32.07%	Perf Year	5.65%
Cash/sh	4.08	P/FCF	30.11	EPS past 3/5Y	- -	ROIC	2.08%	52W Low	22.61 42.15%	Perf 3Y	61.10%
Dividend Est.	-	EV/EBITDA	36.72	Sales past 3/5Y	26.63% 29.93%	Gross Margin	66.44%	Volatility	3.93% 3.69%	Perf 5Y	4.55%
Dividend TTM	-	EV/Sales	4.71	EPS Y/Y TTM	145.78%	Oper. Margin	8.04%	ATR (14)	1.18	Perf 10Y	263.57%
Dividend Ex-Date	-	Quick Ratio	5.10	Sales Y/Y TTM	19.91%	Profit Margin	5.50%	RSI (14)	60.84	Recom	1.55
Dividend Gr. 3/5Y	- -	Current Ratio	5.43	EPS Q/Q	-116.82%	SMA20	4.74%	Beta	2.10	Target Price	41.22
Payout	0.00%	Debt/Eq	0.04	Sales Q/Q	13.75%	SMA50	15.36%	Rel Volume	0.18	Prev Close	31.87
Employees	824	LT Debt/Eq	0.04	Earnings	Aug 06 AMC	SMA200	-2.56%	Avg Volume	1.44M	Price	32.14
IPO	Oct 30, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	57.65% 7.56%	Trades		Volume	188,470	Change	0.85%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-20-25	Initiated	Craig Hallum	Buy	$45
Dec-05-24	Downgrade	Goldman	Buy → Neutral	$38 → $37
Nov-15-24	Initiated	Wolfe Research	Outperform	$50
Oct-16-24	Initiated	UBS	Buy	$43
Oct-10-24	Initiated	Guggenheim	Buy	$40
Feb-23-24	Reiterated	Needham	Buy	$30 → $33
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$33
Jan-07-22	Initiated	Stephens	Overweight	$52
Nov-18-21	Resumed	Goldman	Buy	$60
Jun-15-21	Initiated	Raymond James	Outperform	$45
Feb-18-21	Resumed	Needham	Buy	$88
Jan-28-21	Initiated	Truist	Buy	$61
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight	$48
Sep-09-20	Initiated	Morgan Stanley	Underweight	$35
Jul-31-19	Initiated	Lake Street	Buy	$35
Jul-02-19	Initiated	Needham	Buy	$33
Nov-29-18	Downgrade	Janney	Buy → Neutral
Oct-31-18	Upgrade	Janney	Neutral → Buy
Nov-07-17	Downgrade	Piper Jaffray	Overweight → Neutral

Show Previous Ratings

Sep-09-25 09:00AM	Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting (Business Wire)
Sep-01-25 09:45AM	Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio (Zacks)
Aug-29-25 08:30AM	Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today (Zacks)
08:30AM	Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference (Business Wire)
Aug-27-25 11:25AM	Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer (Business Wire)
08:42AM	Loading…
Aug-26-25 08:42AM	Tempus' Key Acquisitions Strengthen Its AI Healthcare Leadership (Zacks)
Aug-25-25 09:09AM	Is the Options Market Predicting a Spike in Veracyte Stock? (Zacks)
Aug-22-25 09:50AM	Here's Why Veracyte (VCYT) is a Strong Momentum Stock (Zacks) +5.33%
Aug-15-25 09:45AM	Here's Why Veracyte (VCYT) is a Strong Growth Stock (Zacks)
Aug-12-25 08:21AM	VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up (Zacks)
Aug-07-25 09:00AM	Helix and Veracyte Partner to Expand Access to Clinically Actionable Genomic Insights in Prostate Cancer Care (PR Newswire) +15.48%
Aug-06-25 06:35PM	Veracyte (VCYT) Tops Q2 Earnings and Revenue Estimates (Zacks)
05:32PM	Veracyte: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Veracyte Announces Second Quarter 2025 Financial Results (Business Wire)
Aug-05-25 09:45AM	Veracyte Inc (VCYT) Q2 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
08:03AM	Loading…
Jul-28-25 08:03AM	Veracyte (VCYT) Soars 7.0%: Is Further Upside Left in the Stock? (Zacks)
Jul-26-25 11:04AM	Veracyte (VCYT) Soars 7% on S&P SmallCap 600 Inclusion (Insider Monkey)
Jul-24-25 05:58PM	Veracyte Set to Join S&P SmallCap 600 (PR Newswire) +7.04%
Jul-17-25 05:30PM	Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025 (Business Wire)
Jul-16-25 08:38AM	Should You Continue to Hold Veracyte Stock in Your Portfolio Now? (Zacks)
Jul-08-25 04:05PM	Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025 (Business Wire)
Jul-07-25 09:55AM	Tempus AI Boosts R&D Efforts Through Wide-Ranging Product Launches (Zacks)
Jun-06-25 11:31AM	Veracyte (VCYT) Down 13.6% Since Last Earnings Report: Can It Rebound? (Zacks)
May-29-25 12:05AM	Veracyte, Inc. (VCYT) Presents Breakthrough Genomic Data to Predict Cancer Therapy Response at ASCO (Insider Monkey)
May-28-25 04:05PM	Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research (Business Wire)
May-20-25 05:00PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
May-19-25 08:38AM	Veracyte Stock Surges 30.9% in a Year: What's Driving the Rally? (Zacks)
May-09-25 01:29PM	Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up (Zacks)
May-08-25 12:00PM	What Makes Veracyte (VCYT) a New Buy Stock (Zacks)
03:27AM	Veracyte Inc (VCYT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions (GuruFocus.com)
12:50AM	Loading…
12:50AM	Veracyte projects strong Decipher and Afirma growth, targets 22.5% adjusted EBITDA margin for 2025 (Seeking Alpha)
12:49AM	Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
May-07-25 06:55PM	Veracyte (VCYT) Q1 Earnings and Revenues Beat Estimates (Zacks)
06:02PM	Veracyte: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Veracyte Announces First Quarter 2025 Financial Results (Business Wire)
May-06-25 03:20PM	Veracyte Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
May-05-25 05:35PM	Ekso Bionics (EKSO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Apr-25-25 07:00AM	Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer (Business Wire)
Apr-22-25 09:00AM	Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting (Business Wire)
Apr-21-25 04:05PM	Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institutes SEER Specialized Database Release (Business Wire)
Apr-17-25 04:15PM	The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It. (Investor's Business Daily)
09:12AM	Should You Continue to Hold Veracyte Stock in Your Portfolio? (Zacks)
Apr-16-25 06:30PM	Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025 (Business Wire)
Apr-15-25 09:50AM	Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term (Zacks)
Apr-14-25 12:18PM	International Growth Drives GMED Stock Amid Fierce Competition (Zacks)
09:45AM	Here's Why Veracyte (VCYT) is a Strong Growth Stock (Zacks)
08:24AM	Bruker Stock May Benefit Following Its Investment in Ridom GmbH (Zacks)
Apr-11-25 10:01AM	Bruker Debuts Fourier 80 Multinuclear Benchtop FT-NMR: Stock to Gain? (Zacks) +5.12%
Apr-10-25 09:35AM	Veracyte (VCYT) Just Overtook the 20-Day Moving Average (Zacks) -7.27%
09:04AM	Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength? (Zacks)
08:30AM	Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago (Zacks)
Apr-03-25 09:00AM	Should You Continue to Hold Bio-Rad Stock in Your Portfolio? (Zacks) -5.51%
Apr-01-25 08:24AM	Is This the Right Time to Hold ALGN Stock in Your Portfolio? (Zacks)
Mar-28-25 06:08PM	Veracyte (VCYT) Introduces AI-Powered Cancer Detection - Faster and More Accurate Than Ever! (Insider Monkey)
Mar-27-25 08:08AM	Is Quest Diagnostics Stock Worth Holding Onto Right Now? (Zacks)
07:14AM	National Vision Stock Rises 28.2% YTD: Will the Rally Continue? (Zacks)
Mar-26-25 11:30AM	Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue? (Zacks) -7.84%
09:55AM	Wall Street Analysts Believe Veracyte (VCYT) Could Rally 35.05%: Here's is How to Trade (Zacks)
08:31AM	Is This the Right Time to Hold Integra Stock in Your Portfolio? (Zacks)
Mar-25-25 04:05PM	New Data Demonstrate Accuracy of Veracytes Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer (Business Wire)
Mar-21-25 08:22AM	GMED Stock Jumps 41.8% in a Year: What's Behind the Rally? (Zacks)
Mar-19-25 05:00PM	Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25 (Business Wire)
10:02AM	Should You Hold Globus Medical Stock in Your Portfolio Now? (Zacks)
Mar-10-25 09:00AM	Veracyte (VCYT) Surged on Reporting Strong Earnings (Insider Monkey) -5.12%
Feb-25-25 12:22PM	Q4 2024 Veracyte Inc Earnings Call (Thomson Reuters StreetEvents) -14.99%
02:03AM	Veracyte Inc (VCYT) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
Feb-24-25 05:30PM	Veracyte (VCYT) Q4 Earnings and Revenues Beat Estimates (Zacks)
04:41PM	Veracyte: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-22-25 04:14PM	What To Expect From Veracyte Inc (VCYT) Q4 2024 Earnings (GuruFocus.com)
Feb-19-25 05:05PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
Feb-14-25 03:47PM	Schrodinger Stock Scores IBD Rating Upgrade (Investor's Business Daily)
08:30AM	New Data at ASCO GU Show Power of Veracytes Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research (Business Wire)
Feb-11-25 08:30AM	Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium (Business Wire)
Feb-05-25 08:30AM	New Study Shows Veracytes Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer (Business Wire)
Feb-04-25 04:30PM	Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025 (Business Wire)
Dec-12-24 10:39AM	Why Veracyte, With 55% Growth In 2024, Is An Outlier In Cancer Diagnostics (Investor's Business Daily)
09:18AM	Veracyte (VCYT) Shares Rebounded in Q3 (Insider Monkey)
Dec-05-24 04:05PM	Veracytes Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN Prostate Cancer Guidelines (Business Wire)
Nov-27-24 04:51PM	Four Reasons To Watch This AI Play. A Fresh Breakout Is Just One. (Investor's Business Daily)
Nov-07-24 10:01AM	Veracyte Inc (VCYT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Outlook (GuruFocus.com)
Nov-06-24 06:10PM	Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates (Zacks)
05:05PM	Veracyte: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Veracyte Announces Third Quarter 2024 Financial Results (Business Wire)
Nov-05-24 07:43AM	What To Expect From Veracyte Inc (VCYT) Q3 2024 Earnings (GuruFocus.com)
Oct-30-24 05:00PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
Oct-16-24 06:43PM	Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024 (Business Wire)
Oct-09-24 05:07PM	Veracyte Inc (VCYT) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance (GuruFocus.com)
Oct-02-24 05:02PM	Vanguard Group Inc's Strategic Acquisition of Veracyte Inc Shares (GuruFocus.com)
08:20AM	New Data Presented at ASTRO 2024 Show that Veracytes Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men (Business Wire)
Sep-15-24 08:45AM	New Data Presented at ESMO 2024 Show that Veracytes Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer (Business Wire)
Sep-06-24 07:01PM	Insider Sale: Chief Commercial Officer-CLIA John Leite Sells Shares of Veracyte Inc (VCYT) (GuruFocus.com)
Sep-05-24 11:31AM	Veracyte (VCYT) Up 9.2% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-04-24 04:05PM	Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors (Business Wire)
09:50AM	Here's Why Veracyte (VCYT) is a Strong Momentum Stock (Zacks)
Aug-26-24 05:30PM	Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
09:00AM	Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle (Business Wire)
04:36AM	Here's Why Baron Discovery Fund Increased its Holdings in Veracyte (VCYT) (Insider Monkey)
Aug-19-24 09:55AM	Veracyte (VCYT) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Aug-15-24 09:50AM	Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term (Zacks)

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stapley Marc	Chief Executive Officer	Sep 04 '25	Sale	30.41	7,667	233,133	334,185	Sep 08 04:33 PM
MARC STAPLEY	Director	Sep 04 '25	Proposed Sale	30.62	7,667	234,764		Sep 04 04:26 PM
EASTHAM KARIN	Director	Jun 13 '25	Sale	26.66	4,590	122,388	13,907	Jun 17 04:21 PM
Bhanji Muna	Director	Jun 13 '25	Sale	26.67	4,589	122,367	29,989	Jun 17 04:21 PM
KARIN EASTHAM	Director	Jun 13 '25	Proposed Sale	26.69	4,590	122,507		Jun 13 04:46 PM
MUNA BHANJI	Director	Jun 13 '25	Proposed Sale	26.69	4,589	122,480		Jun 13 04:45 PM
Leite John	Chief Commercial Officer-CLIA	Jun 04 '25	Sale	27.20	2,809	76,410	94,540	Jun 06 04:19 PM
JOHN LEITE	Officer	Jun 04 '25	Proposed Sale	26.50	2,809	74,438		Jun 04 04:21 PM
Leite John	Chief Commercial Officer-CLIA	Mar 07 '25	Sale	31.66	7,411	234,630	100,249	Mar 10 04:43 PM
JOHN LEITE	Officer	Mar 07 '25	Proposed Sale	32.51	7,411	240,932		Mar 07 04:17 PM
ANN MCGUIRE	Officer	Mar 04 '25	Proposed Sale	33.56	1,142	38,326		Mar 04 05:12 PM
MARC STAPLEY	Director	Mar 04 '25	Proposed Sale	33.56	52,697	1,768,511		Mar 04 05:07 PM
PHILLIP FEBBO	Officer	Mar 04 '25	Proposed Sale	33.56	8,037	269,722		Mar 04 05:07 PM
Leite John	Chief Commercial Officer-CLIA	Feb 27 '25	Sale	33.84	5,746	194,445	79,070	Mar 03 04:30 PM
Chambers Rebecca	Chief Financial Officer	Feb 03 '25	Sale	43.85	527	23,109	113,510	Feb 05 04:49 PM
EPSTEIN ROBERT S	Director	Jan 06 '25	Option Exercise	8.04	20,000	160,800	64,598	Jan 08 04:47 PM
EASTHAM KARIN	Director	Jan 02 '25	Option Exercise	5.28	10,000	52,800	28,497	Jan 06 05:16 PM
EASTHAM KARIN	Director	Jan 02 '25	Sale	40.30	10,000	403,006	18,497	Jan 06 05:16 PM
KARIN EASTHAM	Director	Jan 02 '25	Proposed Sale	39.60	10,000	396,000		Jan 02 04:23 PM
Stapley Marc	Chief Executive Officer	Dec 13 '24	Sale	43.42	5,590	242,737	307,345	Dec 17 04:31 PM
MARC STAPLEY	Director	Dec 13 '24	Proposed Sale	44.40	5,590	248,196		Dec 13 04:27 PM
Febbo Phillip G.	Chief Scientific & Med Officer	Dec 04 '24	Sale	44.09	3,934	173,447	82,414	Dec 06 04:34 PM
McGuire Annie	SVP, General Counsel	Dec 04 '24	Sale	44.02	18,699	823,179	72,869	Dec 06 04:34 PM
PHILLIP G FEBBO	Officer	Dec 04 '24	Proposed Sale	44.09	1,311	57,802		Dec 05 05:24 PM
Leite John	Chief Commercial Officer-CLIA	Dec 03 '24	Sale	43.25	1,050	45,408	73,810	Dec 04 04:59 PM
Chambers Rebecca	Chief Financial Officer	Dec 03 '24	Sale	43.23	7,000	302,622	114,037	Dec 04 04:59 PM
Wygant Jonathan	VP, Chief Accounting Officer	Dec 03 '24	Sale	43.36	956	41,452	40,270	Dec 04 04:59 PM
PHILLIP G FEBBO	Officer	Dec 04 '24	Proposed Sale	43.66	2,623	114,520		Dec 04 04:38 PM
ANN MCGUIRE	Officer	Dec 04 '24	Proposed Sale	43.66	18,699	816,398		Dec 04 04:35 PM
REBECCA CHAMBERS	Officer	Dec 03 '24	Proposed Sale	44.12	7,527	332,091		Dec 03 04:32 PM
JOHN LEITE	Officer	Dec 03 '24	Proposed Sale	44.12	1,050	46,326		Dec 03 04:31 PM
Wygant Jonathan	VP, Chief Accounting Officer	Nov 27 '24	Sale	42.89	5,032	215,834	42,313	Nov 29 02:28 PM
EASTHAM KARIN	Director	Nov 19 '24	Sale	38.34	14,731	564,768	18,497	Nov 21 04:36 PM
KARIN EASTHAM	Director	Nov 19 '24	Proposed Sale	36.71	14,731	540,775		Nov 19 04:23 PM
Chambers Rebecca	Chief Financial Officer	Nov 12 '24	Sale	38.34	15,275	585,663	124,501	Nov 14 04:35 PM
EPSTEIN ROBERT S	Director	Nov 12 '24	Option Exercise	8.04	15,000	120,600	59,598	Nov 14 04:35 PM
EPSTEIN ROBERT S	Director	Nov 12 '24	Sale	38.32	15,000	574,830	44,598	Nov 14 04:35 PM
ROBERT S EPSTEIN	Director	Nov 12 '24	Proposed Sale	38.89	15,000	583,350		Nov 12 04:29 PM
REBECCA CHAMBERS	Officer	Nov 12 '24	Proposed Sale	38.89	15,275	594,045		Nov 12 04:29 PM
JONES EVAN/ FA	Director	Sep 19 '24	Sale	35.23	5,173	182,263	0	Sep 23 04:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VCYT

Veracyte Inc

Upgrade your FINVIZ experience